Sign In

Gregory A. Otterson MD


Gregory A. Otterson MD
ProfessorCollege of Medicinegreg.otterson@osumc.edu
B450 Starling Loving Hall 320 W 10th Avenue Columbus OH 43210
Phone:614-293-9424Fax: 614-293-4372
  • Molecular Biology and Cancer Genetics
  • Non-aligned Member

General Research Interest

Experimental Therapeutics of Thoracic Malignancies, Epigenetics of Thoracic Malignancies (including microRNA)

Research Description

Dr. Otterson is broadly interested in improving the care and understanding of thoracic malignancies (adenocarcinoma, squamous carcinoma, large cell carcinoma, never-smoking adenocarcinoma, small cell lung cancer, mesothelioma and thymic cancers).  His research centers around the genetic and epigenetic changes in lung cancers, particularly microRNAs.  Therapeutically, he is interested in understanding how better to target specific therapies to specific patients – i.e. understanding which patients will respond to which therapeutic maneuvers

Transinstitutional Work

Dr. Otterson has active collaborations within OSU, including in the Division of Cancer Genetics (Carlo Croce), the School of Public Health (Mary Ellen Wewers and Amy Ferketich), and the Division of Pulmonary and Critical Care Medicine (Patrick Nana-Sinkam).  Outside of OSU, he works with investigators at the University of Minnesota, and also actively works with the Cancer and Leukemia Group B, having been National Principal Investigator on three studies through the Respiratory Committee.

Current Publications

  • Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab TA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Invest New Drugs 31(3) 685-95 6/1/2013
  • Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
  • Ferketich AK, Niland JC, Mamet R, Zornosa C, D'Amico TA, Ettinger DS, Kalemkerian GP, Pisters KM, Reid ME, Otterson GASmoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort.Cancer 119(4) 847-53 2/15/2013
  • Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GAPhase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.Cancer Chemother Pharmacol 71(1) 115-21 1/1/2013
  • Gandhi L, Drappatz J, Ramaiya NH, Otterson GAHigh-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.J Thorac Oncol 8(1) e3-5 1/1/2013
  • Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MAA phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer 79(1) 27-32 1/1/2013
  • Martin LK, Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab TA dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.Int J Radiat Oncol Biol Phys 84(4) e475-81 11/15/2012
  • Martin LK, Otterson GA, Bekaii-Saab TPhotodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series.Photomed Laser Surg 30(11) 668-71 11/1/2012
  • Wu Y , Duan W, Otterson GA, Lee L, Nana-Sinkam PResearch Highlight: miRNA and platinum-based chemotherapy response in non-small-cell lung cancerPersonalized Medicine 9 329-32 11/1/2012
  • Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KMNon-small cell lung cancer.J Natl Compr Canc Netw 10(10) 1236-71 10/1/2012
  • Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R, Camidge DRA phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.Ann Oncol 23(8) 2094-102 8/1/2012
  • Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KMFirst-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.J Natl Compr Canc Netw 10(7) 847-56 7/1/2012
  • Jahan T, Gu L, Kratzke R, Dudek A, Otterson GA, Wang X, Green M, Vokes EE, Kindler HLVatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).Lung Cancer 76(3) 393-6 6/1/2012
  • Ferketich AK, Otterson GA, King M, Hall N, Browning KK, Wewers MEA pilot test of a combined tobacco dependence treatment and lung cancer screening program.Lung Cancer 76(2) 211-5 5/1/2012
  • Dudek AZ, Pang H, Kratzke RA, Otterson GA, Hodgson L, Vokes EE, Kindler HLPhase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.J Thorac Oncol 7(4) 755-9 4/1/2012
  • Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, Klippenstein D, Lackner RP, Leard L, Leung AN, Massion PP, Meyers BF, Munden RF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Schabath MB, Sequist LV, Tong BC, Travis WD, Unger M, Yang SCLung cancer screening.J Natl Compr Canc Netw 10(2) 240-65 2/1/2012
  • West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia RA novel classification of lung cancer into molecular subtypes.PLoS One 7(2) e31906 1/1/2012
  • Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SCMalignant pleural mesothelioma.J Natl Compr Canc Netw 10(1) 26-41 1/1/2012
  • Schuette W, Krzakowski MJ, Massuti B, Otterson GA, Lizambri R, Wei H, Berger DP, Chen YRandomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.J Thorac Oncol 7(1) 157-64 1/1/2012
  • Zhao W, Huang CC, Otterson GA, Leon ME, Tang Y, Shilo K, Villalona MAAltered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.J Oncol 2012 957437 1/1/2012
  • Bertino EM, Otterson GARomidepsin: a novel histone deacetylase inhibitor for cancer.Expert Opin Investig Drugs 20(8) 1151-8 8/1/2011